solarvest bioenergy news

Solarvest Releases an Operational Update

(TheNewswire)



TheNewswire - August 24 th 2021 -  Solarvest BioEnergy Inc. ("Solarvest", or the "Company") (TSXV:SVS), The company is please to offer this operational update.  The company has advanced on many fronts since the recent financing.  The focus has been on expansion of the organic Omega-3 product line for white label sales to large and influential companies based in the USA.  The initial response has been positive as many companies are formulating with our ingredient and assessing our value-added products

The company has advanced the animal health project from bench top studies to scale-up fermentation.  Bench trials with the experimental media have proved successful and the program will now move to larger bioreactor studies followed by optimization, strain analysis and costing studies.

The Seafood project has completed extensive analysis of the plant-based market.  A regulatory and nutritional gap analysis was completed. The project moves on to the formulation of a product that will be sold to customers as a nutritional supplement to be added to plant-based products in order to meet the minimum daily requirements offered in seafood products.

The company is also reporting that it has completed an extensive customer survey using a US mom's marketing group which runs market research/promotion and sampling studies.  The samples were sent to 2000 US mothers who tasted and commented on the Eversea Children's product. The majority of the response was positive, specifically complementing organic certification and the clean label/ingredients.  We are introducing a larger and visually improved gummy for our B to B interested customers and for our branded sales units which will be offered for public sale in September.

The company's sales group has been working with potential white label customers.  NDAs have been signed where required. The organic omega-3 ingredient has been formulated into value added products such as powder boosters, specialty drinks, shots and a grocery product to meet the needs of these customers.

The company has signed a representation/sales agency agreement with Modus Operandi Ltd.'s principal, Dr. Christopher Daugherty, who has extensive market connections and is supporting relationship growth between farmers and brands in the regenerative/Biodynamic space, focusing on brand management, awareness and distribution in the natural products marketplace

About Solarvest

Solarvest BioEnergy Inc. is an algae biologics company whose production platform provides it with an extremely flexible system capable of producing numerous products from Omega 3 fatty acids to human therapeutic proteins. The company has successfully developed, patented and produced the worlds only plant-based organic certified Omega -3 to satisfy the substantial demand for this essential nutrient.  The company has also initiated a program for the expression of CBD and THC to be produced in GMP fermentation facilities.

For further information contact:

Email: invest@solarvest.ca

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Statements made in this news release may contain forward-looking statements that may involve a number of risks and uncertainties.  Actual events or results could differ materially from the Company's expectations and projections.

Copyright (c) 2021 TheNewswire - All rights reserved.

News Provided by TheNewsWire via QuoteMedia

The Conversation (0)
  BPH Global Ltd

BP8 to Expand Seaweed R&D Activities into Essential Mineral Extraction Utilising AI Search Technology; Carbon Credits

The Board of BPH Global Ltd (ASX: BP8) (Company) is pleased to announce that the Company is expanding the nature of its business to include the following projects:

Keep reading...Show less
Sirona Biochem Receives Commercial-Grade GlycoProteMim Based Anti-Aging Serum Formulations

Sirona Biochem Receives Commercial-Grade GlycoProteMim Based Anti-Aging Serum Formulations

Sirona Biochem Corp . (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (" Sirona " or the " Company ") announces a significant achievement in its quest to transform the skincare industry. Its subsidiary, TFChem, has successfully received formulations for its eagerly awaited GlycoProteMim™ based anti-aging serum from its formulation partner, Global Beauty Consulting (GBC). This marks a crucial step in Sirona Biochem's plan to offer innovative skincare solutions.

The chosen formulation will not only define the brand but also lay the foundation for a broader range of products. The team is in the process of selecting the precise formulation that will undergo standard safety evaluations and be used in the upcoming clinical trial. This is in preparation for the planned product launch in early 2025, ensuring compliance with regulatory standards in the European, US, and Canadian markets.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
double helix molecule with word "etf"

5 Small Biotech ETFs to Watch (Updated 2024)

Thanks to exchange-traded funds (ETFs), investors don’t have to be tied to one specific stock. Biotech ETFs allow market participants to gain leverage in multiple biotech companies via one investment vehicle.

The life science sector can certainly be risky, and ETFs are a good way to enter more safely than by investing in standalone stocks. A key advantage is that even if one company in the ETF takes a hit, the impact will be less direct.

Below the Investing News Network takes a look at five small biotech ETFs for investors to consider. They were selected using ETFdb.com, and their total assets under management (AUM) were under US$100 million as of March 8, 2024. All other figures were also current as of that date. Read on to learn more about these investment vehicles.

Keep reading...Show less

AMGEN PRESENTS NEW RESEARCH ON OTEZLA® AT AAD 2024

SPROUT 52-Week Data Demonstrate Durable Response and Consistent Safety Profile of Oral Otezla in Children with Moderate to Severe Plaque Psoriasis

Late-Breaking Phase 3 Study of Otezla in Palmoplantar Pustulosis Achieves Primary and Secondary Endpoints at 16 Weeks

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
Collage with hands holding shiny DNA molecule on blue background.

5 Biggest Biotechnology ETFs in 2024

Investing in the biotech industry can be a long road to gains given the sector’s volatility.

Even with a good understanding of the system, no one can predict which treatment, device or therapy will give the biggest return, making biotech exchange-traded funds (ETFs) a more secure option than individual biotech stocks.

An ETF is a relatively safe investment route that can minimize losses while offering exposure to multiple companies instead of focusing on the gains and losses of a single biotech stock. With that in mind, here’s a brief look at the five top biotechnology ETFs by total assets. Data was sourced from ETFdb.com on March 1, 2024, and all data was current as of that time.

Keep reading...Show less

AMGEN ANNOUNCES 2024 SECOND QUARTER DIVIDEND

Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.25 per share dividend for the second quarter of 2024. The dividend will be paid on June 7, 2024 to all stockholders of record as of the close of business on May 17, 2024 .

About Amgen
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×